Latest Pharma and Biotech News
Biotechnology
18 March 2025 US biotech Incyte has reported positive results from two Phase III trials of povorcitinib, an oral JAK1 inhibitor.
Today's issue
Refine Search
Biotechnology
US genetic medicin0es firm Arbor Biotechnologies has announced the closing of a $73.9 million Series C financing to support the advancement of its pipeline of novel gene editing therapeutics targeting diseases in the liver and central nervous system (CNS). 19 March 2025
Biotechnology
Immunovant, a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab in myasthenia gravis (MG) and initial results from Period 1 of its Phase IIb study in chronic inflammatory demyelinating polyneuropathy (CIDP). 19 March 2025
Pharmaceutical
French independent pharma firm Servier and USA-based Black Diamond Therapeutics, a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class targeted therapy for solid tumors 19 March 2025
Biotechnology
Genetic medicine firm Sarepta Therapeutics announced the tragic death of a young man with Duchenne muscular dystrophy (DMD) following treatment with the company’s gene therapy Elevidys (delandistrogene moxeparvovec-rokl). 19 March 2025
Biotechnology
US biotech Stoke Therapeutics, which is dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, yesterday revealed that Dr Edward Kaye has decided to step down from his role as chief executive (CEO) effective as of March 19, 2025. The firm’s shares dipped 3% following the announcement. 19 March 2025
Biotechnology
Chinese pair Hutchmed and Innovent Biologics have announced that the FRUSICA-2 Phase II/III trial of fruquintinib and sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (RCC) in China has met its primary endpoint. 19 March 2025
Pharmaceutical
Newly-appointed US Health and Human Services (HHS) Secretary Robert F Kennedy Jr has renewed the public health emergency declaration addressing the USA’s opioid crisis, which will allow sustained federal coordination efforts and preserve key flexibilities that enable HHS to continue leveraging expanded authorities to conduct certain activities in response to the opioid overdose crisis. 19 March 2025
Pharmaceutical
Belgium’s largest drugmaker UCB today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living with thymidine kinase 2 deficiency (TK2d), at this year’s MDA Clinical and Scientific Conference, Dallas, Texas. 19 March 2025
Biotechnology
RegCell, a Japanese-founded biotechnology company, has announced the closing of an oversubscribed seed round and its transition to a USA-based company, based in Emeryville, California. 19 March 2025
Biotechnology
Privately-held Chinese firm Visirna Therapeutics has announced that a Phase III trial of VSA001 (plozasiran) has met both its primary and all key secondary endpoints. 18 March 2025
Pharmaceutical
Budget limitations and health crises are a constant in several countries in the Americas, impacting not only the population, but also the pharmaceutical industry which, in some cases, does not benefit from solid regulatory bases to promote research or regulate innovative medicines, given that there are many cumbersome procedures and financial instability. 18 March 2025
Biotechnology
Shares of French late-stage clinical biotech firm Nanobiotix leapt 17.6% to 3.47 euros after it announced the execution of another disciplined step in its financial strategy through the amendment of its global licensing agreement with Johnson & Johnson subsidiary Janssen entered into in 2023 to develop its radioenhancer NBTXR3. 18 March 2025
Pharmaceutical
Privately-held Italian pharma company Italfarmaco and Slovenia-based Medis Therapeutics have announced an exclusive distribution agreement for givinostat, the former company’s drug for the treatment of Duchenne muscular dystrophy (DMD). 18 March 2025
Pharmaceutical
Israeli-headquartered RedHill Biopharma today revealed its plan to submit a UK marketing authorization application (MAA) for Talicia (low-dose rifabutin-triple therapy) for treatment of helicobacter pylori (H. pylori) infection under the Medicines and Healthcare products Regulatory Agency's (MHRA) International Recognition Procedure (IRP). 18 March 2025
Biotechnology
European life sciences venture capital firm Sofinnova Partners and French cancer research hospital Gustave Roussy have announced the creation of their first biotech company. 18 March 2025
Pharmaceutical
Pharma market insights provider Evaluate today released its 2025 Orphan Drug Report highlighting forecasts for the orphan drug market out to 2030. 18 March 2025
Biotechnology
Forth Therapeutics, a UK biotechnology company focused on precision treatments for fibrosis, has launched with support from European venture capital firm Sofinnova Partners and Old College Capital, the University of Edinburgh’s investment arm. 18 March 2025
Biotechnology
US biotech Incyte has reported positive results from two Phase III trials of povorcitinib, an oral JAK1 inhibitor. 18 March 2025
Pharmaceutical
Seattle, USA-based biotech Curevo Vaccine, which is developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the closing of a $110 million Series B round to advance development of amezosvatein, its vaccine for shingles. 18 March 2025
Pharmaceutical
Scottish gut health specialist EnteroBiotix has announced positive initial results with EBX-102-02, its full-spectrum microbiome product, from the TrIuMPH Phase IIa trial in adults with irritable bowel syndrome with constipation (IBS-C). 18 March 2025
All news
Biotechnology
US genetic medicin0es firm Arbor Biotechnologies has announced the closing of a $73.9 million Series C financing to support the advancement of its pipeline of novel gene editing therapeutics targeting diseases in the liver and central nervous system (CNS). 19 March 2025
Biotechnology
Immunovant, a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab in myasthenia gravis (MG) and initial results from Period 1 of its Phase IIb study in chronic inflammatory demyelinating polyneuropathy (CIDP). 19 March 2025
Pharmaceutical
French independent pharma firm Servier and USA-based Black Diamond Therapeutics, a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class targeted therapy for solid tumors 19 March 2025
Biotechnology
Genetic medicine firm Sarepta Therapeutics announced the tragic death of a young man with Duchenne muscular dystrophy (DMD) following treatment with the company’s gene therapy Elevidys (delandistrogene moxeparvovec-rokl). 19 March 2025
Biotechnology
US biotech Stoke Therapeutics, which is dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, yesterday revealed that Dr Edward Kaye has decided to step down from his role as chief executive (CEO) effective as of March 19, 2025. The firm’s shares dipped 3% following the announcement. 19 March 2025
Biotechnology
Chinese pair Hutchmed and Innovent Biologics have announced that the FRUSICA-2 Phase II/III trial of fruquintinib and sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (RCC) in China has met its primary endpoint. 19 March 2025
Pharmaceutical
Newly-appointed US Health and Human Services (HHS) Secretary Robert F Kennedy Jr has renewed the public health emergency declaration addressing the USA’s opioid crisis, which will allow sustained federal coordination efforts and preserve key flexibilities that enable HHS to continue leveraging expanded authorities to conduct certain activities in response to the opioid overdose crisis. 19 March 2025
Pharmaceutical
Belgium’s largest drugmaker UCB today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living with thymidine kinase 2 deficiency (TK2d), at this year’s MDA Clinical and Scientific Conference, Dallas, Texas. 19 March 2025
Biotechnology
RegCell, a Japanese-founded biotechnology company, has announced the closing of an oversubscribed seed round and its transition to a USA-based company, based in Emeryville, California. 19 March 2025
Biotechnology
Privately-held Chinese firm Visirna Therapeutics has announced that a Phase III trial of VSA001 (plozasiran) has met both its primary and all key secondary endpoints. 18 March 2025
Pharmaceutical
Budget limitations and health crises are a constant in several countries in the Americas, impacting not only the population, but also the pharmaceutical industry which, in some cases, does not benefit from solid regulatory bases to promote research or regulate innovative medicines, given that there are many cumbersome procedures and financial instability. 18 March 2025
Biotechnology
Shares of French late-stage clinical biotech firm Nanobiotix leapt 17.6% to 3.47 euros after it announced the execution of another disciplined step in its financial strategy through the amendment of its global licensing agreement with Johnson & Johnson subsidiary Janssen entered into in 2023 to develop its radioenhancer NBTXR3. 18 March 2025
Pharmaceutical
Privately-held Italian pharma company Italfarmaco and Slovenia-based Medis Therapeutics have announced an exclusive distribution agreement for givinostat, the former company’s drug for the treatment of Duchenne muscular dystrophy (DMD). 18 March 2025
Pharmaceutical
Israeli-headquartered RedHill Biopharma today revealed its plan to submit a UK marketing authorization application (MAA) for Talicia (low-dose rifabutin-triple therapy) for treatment of helicobacter pylori (H. pylori) infection under the Medicines and Healthcare products Regulatory Agency's (MHRA) International Recognition Procedure (IRP). 18 March 2025
Biotechnology
European life sciences venture capital firm Sofinnova Partners and French cancer research hospital Gustave Roussy have announced the creation of their first biotech company. 18 March 2025
Pharmaceutical
Pharma market insights provider Evaluate today released its 2025 Orphan Drug Report highlighting forecasts for the orphan drug market out to 2030. 18 March 2025
Biotechnology
Forth Therapeutics, a UK biotechnology company focused on precision treatments for fibrosis, has launched with support from European venture capital firm Sofinnova Partners and Old College Capital, the University of Edinburgh’s investment arm. 18 March 2025
Biotechnology
US biotech Incyte has reported positive results from two Phase III trials of povorcitinib, an oral JAK1 inhibitor. 18 March 2025
Pharmaceutical
Seattle, USA-based biotech Curevo Vaccine, which is developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the closing of a $110 million Series B round to advance development of amezosvatein, its vaccine for shingles. 18 March 2025
Pharmaceutical
Scottish gut health specialist EnteroBiotix has announced positive initial results with EBX-102-02, its full-spectrum microbiome product, from the TrIuMPH Phase IIa trial in adults with irritable bowel syndrome with constipation (IBS-C). 18 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze